Abstract
Autism is a genetic neurodevelopmental disorder of unknown cause and pathogenesis. The identification of genes involved in autism is expected to increase our understanding of its pathogenesis. Infrequently, neurodevelopmental disorders like autism are associated with chromosomal anomalies. To identify candidate genes for autism, we initiated a positional cloning strategy starting from individuals with idiopathic autism carrying a de novo chromosomal anomaly. We report on the clinical, cytogenetic and molecular findings in a male person with autism, no physical abnormalities and normal IQ, carrying a de novo balanced paracentric inversion 46,XY,inv(10)(q11.1;q21.3). The distal breakpoint disrupts the TRIP8 gene, which codes for a protein predicted to be a transcriptional regulator associated with nuclear thyroid hormone receptors. However, no link between thyroid gland and autism has been reported so far. In addition, the same breakpoint abolishes expression of a nearby gene, REEP3, through a position effect. Receptor Expression-Enhancing Proteins (REEP) 3 is one of the six human homologs of yeast Yop1p, a probable regulator of cellular vesicle trafficking between the endoplasmatic reticulum and the Golgi network. These observations suggest that TRIP8 and REEP3 are both positional candidate genes for autism. In addition, our data indicate that in the selection of positional candidate genes when studying chromosomal aberrations, position effects should be taken into account.
Similar content being viewed by others
Introduction
Autism is a severe developmental disorder of the central nervous system of unknown pathogenesis. The prevalence of autism is estimated at about 1/1000 to 1/2000 and the prevalence of autism disorders at about 1/160.1 In 5–10% of individuals with autism, a single underlying cause can be established, such as a chromosomal aberration or a monogenic disorder (eg, the Fragile X syndrome, tuberous sclerosis2, 3 or more rarely, mutations in the NLGN3/4 genes4 and the SHANK3 gene5). In these instances associated physical anomalies are often present. In contrast, in the majority of individuals the autism is isolated and no identifiable single cause can be identified. In these cases, polygenic inheritance is likely in most of them. However, estimates on the number of interacting genes vary from two to 10,6 and it is likely that different combinations of genes may be implicated in unrelated individuals.7
The diagnosis of autism is achieved on purely clinical grounds, given the lack of diagnostic neurobiological or genetic markers. The identification of genes involved in the origin of autism is expected to increase our understanding of the pathogenesis of this disorder. Genetic studies have yielded suggestive linkage and association to several different chromosomal regions, but up to now, the large number of association studies using a candidate gene approach has had limited success.8, 9, 10, 11 As an alternative approach, the characterization of different types of chromosomal abnormalities could result in the identification of candidate genes for autism.8, 9, 12 About 5% of autistic patients have a chromosome abnormality visible with cytogenetic methods.13 Almost all chromosomes have been involved including translocations and inversions resulting in disruption of genes at the breakpoints (eg,14, 15), and interstitial or terminal deletions and duplications resulting in gene-dosage effects of 10s of genes.12, 16, 17 The most frequently reported imbalances are 15q11–q13 duplication18 and 2q37 deletion.19 However most imbalances remain undetectable using routine karyotype analysis. Recent technological developments, such as array-based comparative genomic hybridization (aCGH), allow the investigation of the human genome at a much higher resolution and resulted in the identification of different cryptic imbalances and the fine mapping of the 15q duplication in autism.13, 20, 21
At the Center, we initiated a positional cloning strategy starting form both classical karyotyping8 and aCGH.22 As previously reported, in a group of 525 individuals with isolated, sporadic autism, we identified four patients carrying a de novo chromosomal aberration using routine karyotyping.8, 14 The incidence of such apparently balanced aberrations in this population of patients with autism is much higher than expected from the low incidence in the normal population (1/10 000 for a paracentric inversion and 1/2000 for a reciprocal translocation23, 24). Together with the de novo origin of the aberrations and negative family histories for autism, this suggests that at least in some of these individuals, there is a causal relationship between the chromosome aberration and the occurrence of autism. Here, we describe the detailed molecular genetic analysis of a boy with autism carrying a de novo balanced paracentric inversion 46,XY,inv(10) with breakpoints in chromosome 10q21.3 and the centromere of chromosome 10.
Materials and methods
Positional cloning of the inversion breakpoint
Was performed as described before.14 Electronic-database information and all primers used are provided online as Supplementary Information.
Southern blot analysis
Genomic DNA of the patient and a control was treated with spermidine, digested with EcoRI enzyme and electrophoresed on 0.8% agarose gel. Southern blotting and hybridization were carried out according to the standard protocols.25 The filter was hybridized with a 301-bp PCR product from intron 1 of the hTRIP8a-c gene, purified with QIAquick gel extraction kit (Qiagen, Venlo, The Netherlands) and radiolabelled with α-32P-dCTP using the Megaprime DNA labelling system (Amersham Pharmacia Biotech, Roosendaal, The Netherlands).
RT-PCR
Reverse transcriptase (RT-PCR) was used (a) to show that both BC068557 and BC018658 mRNAs are corresponding to the same REEP3 gene, (b) to detect mRNA of all different TRIP8a-c transcripts and (c) to study gene expression using real-time PCR and single-nucleotide polymorphisms (SNPs) (see below). mRNA was isolated from Epstein–Barr virus (EBV) transformed leukocytes of the patients and controls using the Rneasy Midi Kit (Qiagen). Next, mRNA was treated with DNaseI (Gibco BRL, Merelbeke, Belgium,) for 15 min followed by cDNA preparation using the Superscript First Stand Synthesis System for RT-PCR (Invitrogen, Merelbeke, Belgium) with random hexamers. Finally, a standard PCR reaction with 25–30 cycles was performed with the cDNA as a template.
Real-time PCR
Quantitative PCR was performed using qPCR Master Mix for SYBR Green I detection (Eurogentec, Seraign, Belgium) on an ABI PRISM 7000 instrument, in accordance with the manufacturer's guidelines. Primers were developed with Primer Express Software (Applied Biosystems, Foster City, CA, USA). HPRT was used for normalization and the relative expression levels were calculated using the delta delta Ct method.26
Study of gene expression using SNPs
To study the expression of genes at or nearby the breakpoints, SNP analysis was performed at the genomic and mRNA level. First, for reported SNPs in the coding sequence of TRIP8a–c, NRBF-2 and REEP3 we analyzed whether the patient was heterozygous at the genomic level by sequencing the amplified fragment both directly and after subcloning in the pGEM-T easy (Promega, Leiden, The Netherlands). For SNPs for which the patient was heterozygous, the corresponding cDNA sequences were analyzed for the presence of both alleles. As a control, biallelic expression was tested in heterozygous controls. mRNA was isolated from EBV cell lines of the patient and controls using the Rneasy Midi Kit (Qiagen). cDNA was prepared by RT-PCR as described above. DNA and cDNA fragments were amplified by PCR and sequenced using the DNA Sequencing kit (PE Biosystems, Foster City, CA, USA) and the ABI Prism 3100 Genetic Analyser. Primers used for cDNA amplification were chosen in different exons, except for the primer set used to amplify the cDNA fragment from the 3′UTR of REEP3 gene.
Methylation analysis of CpG islands
To investigate the methylation of CpG islands, genomic DNA extracted from peripheral white blood cells of the patient and a control were digested with methylation-independent enzymes cutting at both sides of the island (BamHI for CpG37, EcoRI for CpG122 and CpG125), alone or in combination with methylation-dependent restriction enzymes cutting at or nearby the CpG island (HpaII for CpG37, NotI for CpG 122 and Cfr10I for CpG125). Fragment lengths were analyzed by means of Southern blot analysis and the pattern for patient and control was compared. Probes used for hybridizing the blots were designed in a fragment (a) flanked by restriction sites corresponding with an enzyme independent for methylation, and (b) flanked, at least at one site, by a restriction site for a methylation-dependent enzyme within the fragment obtained after digestion with the methylation independent. Expected lengths for double digestion are: 2.7 kb (methylated) or 1.4 kb (unmethylated) for CpG37, 7.1 kb (methylated) or 4.7 kb (unmethylated) for CpG122, and 9.5 kb (methylated) or 623 bp (unmethylated) for CpG125. As GC% of the CpC122 and CpG125 probes are relatively high (69 and 75%), higher hybridization (57.5°C) and washing temperatures (65°C) were used.
Results
Case report
CK is a 9-year-old boy, referred for child psychiatric assessment because of social and communication problems. He is the third child of non-consanguineous parents. There was no family history of developmental disorders. Pregnancy and delivery were uneventful. There were no signs of dysmaturity. Psychomotor milestones were within normal range. Early language and social development were delayed. Development of fantasy and pretend play were delayed and as a preschooler, CK was fascinated by circling objects. He did not socialize with peers at school. Clinical assessment showed a boy with no dysmorphic signs. Clinical neurological examination was normal. He had marked deficits in social reciprocity, and ‘active-but-odd’ type social interactions. Productive and receptive language were mildly delayed. Non-verbal communication was impaired. He showed perseverative behavior and had problems to adjust to changes. Mood and affect were normal. There were signs of a formal thought disorder. In a special school program, CK had 1-year delay in reading and arithmetics. Wechsler's intelligence scales (WISC revised) showed an uneven intelligence profile within the normal range: performal IQ 106, verbal IQ 93. Theory-of-Mind testing showed marked impairment in social perspective taking. In conclusion, CK fulfilled the criteria for the diagnosis of (high-functioning) autistic disorder according to DSM-IV.27 His mild formal thought disorder is not a typical characteristic in autism.
Molecular analysis
In the patient, a chromosomal inversion was detected with karyotype 46,XY,inv(10)(q11.1;q21.3). Karyotype of the parents was normal. Genome-wide aCGH using a 1 Mb aCGH did not detect a chromosomal imbalance (data not shown). Therefore, the chromosomal anomaly in the patient is a de novo balanced paracentric inversion. The positions of the breakpoints on chromosome 10q were determined by means of FISH on metaphase chromosomes. Cytogenetically the proximal breakpoint was mapped at 10q11.1. However, the centromere probe of chromosome 10 used as a control probe for FISH gave a split signal on the rearranged chromosome 10 (Figure 1b). This revealed that the proximal breakpoint was located in the repetitive sequence of the centromere of chromosome 10. Therefore, the gene(s) implicated in the phenotype must be located at or near the chromosome 10q21.3 breakpoint.
As shown in Figure 1a, the distal breakpoint at 10q21.3 was flanked by BACs RP11-444I9 (NCBI AL607128) and RP11-439F7 (NCBI AL607062). BAC RP11-351O1 (NCBI AC022022, Figure 1c) and cosmids 87d1 (Figure 1c), 14h8 and 29h9 were found to span the breakpoint. Southern blot analysis with a probe from the overlap region of these cosmids showed a rearranged fragment in the DNA of the patient using the EcoRI restriction enzyme (Figure 1d). The breakpoint could thus be localized to a 7.3 kb EcoRI restriction fragment (Figure 1a).
Direct disruption of the TRIP8 gene on 10q21.3
Comparison of sequences of both the cosmid ends and the probe used in the Southern blot study with the human genome sequence, showed that the 10q21.3 breakpoint is located within the first intron of the TRIP8 gene (Figure 1a),28 also known as JMJD1C (UCSC Browser).
Using expressed sequencing tag (EST) data, we identified three alternative transcripts of the TRIP8 gene (Figure 1a and Table 1). The three transcripts use an alternative first exon (see Figure 1a). The existence of all three transcripts of the TRIP8 gene was confirmed by transcript-specific RT-PCR on RNA extracted from an EBV cell line (Figure 2a – right), which yielded fragments of the expected size. For each transcript, one primer was located in the alternative exon 1, the second primer in exon 3 (numbering according to TRIP8a and b). Cloning and sequencing confirmed the identity of the fragments. For both TRIP8a and TRIP8b, a CpG island was identified (CpG 122 and 125, respectively, Figure 1a). However, we could not identify a CpG island (WebGene) or a putative promotor (Promotor Inspector) in the 280 kb region proximal to the breakpoint that could drive the expression of TRIP8c from the derivative chromosome 10q.
From its position in the gene, the chromosomal inversion is expected to disrupt expression of both TRIP8a and TRIP8b transcripts, whereas expression of the alternative TRIP8c transcript may be preserved. By means of real-time PCR on cDNA from EBV cell lines, expression levels of the different TRIP8 transcripts were studied in the patient and compared to controls. Interestingly, ddCt, analysis revealed a twofold decrease in expression of both TRIP8a and TRIP8b, whereas the expression of TRIP8c is clearly unaffected by the chromosomal aberration in the patient (Figure 2b). Ct values of the amplification of the different transcripts in the EBV cell line of control C1 indicate that TRIP8b is expressed in relative low amounts compared to the other transcripts (Figure 2b), which is consistent with the semiquantitative RT-PCR data (Figure 2a – right).
Breakpoint position effect affecting the expression of the REEP3 gene, a yeast Yop1p homolog
As a result of the inversion, 10q21.3. sequences are now juxtaposed to centromere sequences in this patient, and position effects may have occurred in genes more distant from this breakpoint, both distal and proximal. We investigated the methylation pattern of CpG islands and the expression levels of genes, both proximal and distal to the breakpoint (Figure 2a). Using SNPs, we investigated the expression of the genes NRBF-2 (NM_030759) 315 kb proximal, and REEP3 (NM_001001330, formerly known as C10ORF74) 43 kb distal to the breakpoint on an EBV cell line from the subject (Figure 2b and c). The next gene telomeric from REEP3, CTNNA3 is located at a distance of more than 2 Mb and was therefore not studied. For two of the five reported exonic SNPs in the 3′UTR of NRBF-2 (NCBI mRNA AK054957), rs1160843 (−/AAT) and rs13095 (G/C), the patient was heterozygous. Analysis of the corresponding mRNA fragments revealed a normal biallelic expression of this NRBF-2 gene (Figure 2c). However, for the mRNA BC018658 (corresponding to REEP3, see below), the patient was heterozygous for an unreported SNP (G/A) in the 3′ UTR, as shown by sequencing of the amplified DNA containing the polymorphism of interest, both directly and after subcloning (Figure 2c). At the mRNA level only the G-allele was detected, indicating monoallelic expression of this gene (Figure 2b). The possibility of monoallelic expression owing to imprinting of the locus of interest or a preferential amplification of one of the alleles was excluded by studying four heterozygous controls, which showed biallelic expression of the REEP3 gene (shown for one control, Figure 2b).
As shown in Figure 2e, the methylation of the investigated methylation-dependent restriction sites at or nearby CpG island 37 proximal, and islands 122 and 125 distal to the breakpoint in the patient were unaffected by the vicinity of the centromere sequence as compared to control.
Although the unreported G/A SNP was located in the mRNA BC018658, and the UCSC database shows the non-overlapping mRNA BC068557 1200 bp upstream chromosome 10 as the full-length cDNA sequence of REEP3, we showed that both mRNAs correspond to a single gene. First, we identified a cDNA clone (IMAGE562868 (NCBI ESTs AA100605 and AA100609)) containing part of the 3′ end of REEP3 and the entire BC018658 mRNA. In addition, using a sense primer in BC068557 (REEP3 up) and antisense primer in BC018658 (REEP3 low), we were able to amplify a cDNA fragment of the expected size of 1.6 kb, which had the predicted nucleotide sequence, identical to that of the corresponding fragment of the IMAGE562868 clone (data not shown). Interestingly, the transcript was also found on the AceView database, referred to as TB2_DP1_HVA22.4b. In conclusion, the full-length REEP3 gene (NM_001001330) consists of eight exons spanning 104 kb of the human genome at 10q21.3. The gene codes for a transcript of 4677 bp, with a coding sequence of 765 bp (255 AA).
Through BLASTP search, proteins homologous to the predicted protein corresponding to human REEP3 (AAH68557) in other species, like mouse (AAH04607, D10UCla1 gene (NM_178606)), rat (XP_215383, LOC294375 gene (XM_215383)), zebrafish (AAH45373, MGC55529 gene (NM_200161)), Drosophilae (AAM68228, CG30193 gene (NM_166571)), Caenorhabditis elegans (AAC46595, T19C3.4 gene (NM_064820)) and Saccharomyces cerevisiae (CAA07720, Yop1p gene (AJ007902)) were identified. For mouse, rat and zebrafish, we were able to show syntheny between human 10q23.1 and the chromosomal region where the homologous gene was located (chr10 in mouse, chr20 in rat and chr12 in zebrafish). Therefore, the corresponding proteins are true orthologs of the human REEP3 (Supplementary Figure). The yeast Yop1p gene has several homologs in human, of which REEP5/C5orf18 (NM_005669) at 5q22.2 coding for the protein known as TB2/DP1 (AAH65926) is likely to be the true ortholog.29 Alignment of protein sequences of the orthologs and homologs of REEP3 in other species revealed a conserved N-terminal region, corresponding to the ‘TB2/DP1 and HVA22’ domain (Pfam PF03134, Supplementary Figure). Northern blot analysis (not shown) revealed wide expression of this gene, including the central nervous system, which is in accordance with data represented in the public databases (eg, UniGene and Genecards).
Discussion
Progress on the genetic basis of autism has been very slow, despite the numerous linkage and association studies reported over the last 5–10 years.8, 9, 10, 11 Chromosomal abnormalities detected by cytogenetics or aCGH are of major aid to locate relevant genes for any monogenic and polygenic disease.9, 11 Recently, this approach has been successful in the identification of candidate genes for other psychiatric disorders of unknown cause, that is, developmental dyslexia30 and Tourette syndrome.31 Therefore, as an alternative way to identify candidate genes for autism, we analyzed the breakpoint regions of de novo inversion inv(10)(q11.1;q21.3) in an individual with autism. As the proximal breakpoint was found to be located in the repetitive sequence of the centromere, we focused on the gene(s) located at the chromosome 10q21.3 breakpoint. This 10q21.3 breakpoint was located in the first intron of the TRIP8 gene, and resulted in the disruption of at least one of the alternative transcripts we identified for this gene. In addition to this, we also found that the inversion breakpoint abolished expression of the REEP3 gene, located 43 kb distal to the breakpoint. Both disrupted genes are expressed in brain, a requirement for an autism susceptibility gene. However, from a functional point of view, little is known on these two genes.
Two novel positional candidate genes
The TRIP8 gene was recently characterized in silico as a member of the family of thyroid receptor interacting proteins (TRIPs).28 For this gene, we identified two unreported alternative transcripts. Expression analysis on an EBV cell line from the subject suggested that only transcripts TRIP8a and b were disrupted, but not TRIP8c. The function of TRIP8 is currently not known. The predicted TRIP8 protein consists of two bipartite nuclear localization signals, TRI8H1 and TRI8H2 and a JMJC domain.28 Because JMJC domain proteins are implicated in chromatin remodelling,32 TRIP8 was predicted to be a transcriptional regulator associated with nuclear hormone receptors. Consistent with this is the observation that TRIP8 interacts with T3 receptor β in a T3-dependent manner.33 Our finding therefore implicates a possible role for thyroid hormone signalling in the pathogenesis of the autism seen in the present patient. It is well established that thyroid hormones play a critical role in the regulation of brain development,34 and therefore, it has been hypothesized that neurobehavioral disabilities of childhood, including autism35 can be attributed to fetal thyroid endocrine disruption in utero. However, studies investing a possible link between autism and thyroid hormone or T3 receptors remained negative.36, 37, 38, 39 Alternatively, it is not excluded that TRIP8 might have an additional function besides its interaction with TRβ. Nearly all TRIPs interact with the retinoid X receptor,33 and TRIP2 also interacts with other transcription factors, like vitamin D receptor, peroxisome proliferation-activated receptor- alpha and gamma, retinoic acid receptor alpha and, to a lesser extent, estrogen receptor-1.40
Likewise, the second candidate gene REEP3 has not been functionally characterized. It codes for a predicted protein with high homology to proteins in human and several other species. Human REEP3, formerly known as C10ORF74, is a member of the recently described family of Receptor Expression-Enhancing Proteins (REEP).41 In humans, this family consists of six members, but only for the prototype REEP1 a probable function is known, ie transport of G protein-coupled receptors to the cell surface membrane.41 REEP proteins share a common domain called ‘TB2/DP1 and HVA22’, also found in other proteins in several other species. Functional data are available on two homologs, the yeast Yop1p and a plant homolog HVA22, and both reveal a role in cellular vesicle trafficking. Yop1p (Yip one partner) was identified as a probable regulator of cellular vesicle trafficking, as it interacts with Ypt1p (a Rab GTPase required for transport from the endoplasmatic reticulum (ER) to the Golgi complex), as well as with Yip1p (a Ypt1p-interacting protein).42 It is thought that these ‘Rab effector’ complexes serve as cores recruiting different ‘effector partner’ proteins involved in membrane trafficking to their proper subcellular localization. In agreement with the idea that Rab proteins function in all aspects of vesicular transport, their diverse effectors and effector partners have recently been shown to function in all identified aspects of this process.43 Overexpression of Yop1p blocks membrane trafficking, resulting in huge swollen cells of aberrant shape.29 This block was shown to be at the level of the ER, leading to an accumulation of internal membrane structures.29 Interestingly, this phenotype could be rescued by co-expression of Yip1p, further indicating that Yop1p and Yip1p function in a common transport step.29
Expression of the HVA22 plant gene is induced by environmental stresses, such as dehydration, salinity and extreme temperatures and by abscisic acid stress hormone.44 Based on observations about the yeast Yop1p homolog, it has been suggested that HVA22 regulates vesicular traffic in stressed cells, either to facilitate membrane turnover, or to decrease unnecessary secretion.45
Chromosomal breakpoint position effects
Positional cloning of translocation or inversion breakpoints has been a successful way of identifying candidate genes for many genetic disorders. The underlying assumption is that a gene disrupted by the breakpoint is causative of the phenotype. However, in many instances, no genes are detected that are directly disrupted by the breakpoints. This suggests either that the chromosomal aberration is unrelated to the phenotype, or, that genes located at a distance of the breakpoint must be implicated.46 In this study, we show that besides the direct disruption of one gene the expression of another gene, located 43 kb away from the breakpoint, is equally affected. Similarly, genes flanking the 7q11 microdeletion in patients with Williams–Beuren syndrome showed decreased levels of expression.47 In general, a position effect could occur as a result of the disruption of enhancers, or the physical separation of the gene from more distant enhancers. Alternatively, the present chromosomal aberration is unusual, in the way that it results in juxtaposition of genes to centromere repeat sequences. Centromeres are composed of large repetitive DNA domains packaged into a heterochromatin structure. These structures seem to be able to induce a generalized repression of transcription, a phenomenon called ‘position effect variegation’ or silencing.48 The finding of a normal expression of the NRBF-2 gene, 315 kb proximal to the breakpoint, and the apparently normal methylation pattern of the promoter regions of this gene and of the silenced REEP3, TRIP8a and b genes distal to the breakpoint, argues against a more general silencing effect imposed on the region nearby the breakpoint at 10q21.3. Therefore, the most likely mechanism causing disruption of REEP3 expression is the loss of regulatory sequences. As in most (but not all) cases of such position effects, the breakpoint is located at the 5′ position of this gene.49 Nevertheless, as the gene affected by the translocation breakpoint causing the phenotype might be located up to a distance of 1 Mb (eg, SOX9 in Campomelic dysplasia50) additional positional candidate genes might be taken into account. As CTNNA3, the gene closest to REEP3, is located 2.46 Mb distal to the breakpoint, it is most unlikely that genes distal to the breakpoint are affected by a possible silencing effect caused by the aberration. Moreover, as mentioned earlier, normal expression in the patient of both NRBF-2 and TRIP8c genes argues against a silencing effect affecting genes proximal to the breakpoint. Nevertheless, it has been reported that enhancer elements can regulate the expression of a gene at large distant, even with other uninvolved genes located within this genomic region separating enhancer and the regulated gene (eg, SHH at 7q36.3 in preaxial polydactyly51). Taken together, also genes more distant to chromosomal breakpoints should be considered as candidate genes, even when they are separated from the aberration by unaffected genes. Therefore, although unlikely, for the two additional genes within the 1 Mb-region proximal to the 10q21.3 breakpoint, EGR2 (involved in Charcot–Marie–Tooth disease52) at 650 kb and C10orf22 at 655 kb, a silencing effect cannot be completely excluded. Unfortunately, the absence of polymorphisms in de coding sequence of these genes together with low expression levels in EBV cell lines make it currently impossible to investigate this further.
In conclusion, we identified two novel candidate genes, TRIP8 and REEP3, both affected by the 10q21.3 breakpoint of a de novo paracentric inversion in a patient with isolated autism. As the REEP3 gene is not directly disrupted by the aberration, our observation suggests that, when studying chromosomal anomalies, genes located nearby should be considered as positional candidate genes as well. Unfortunately, both the functional data on these genes and our knowledge on the pathogenesis of autism are too limited to allow defining whether or not these two genes are also functional candidate genes for autism. Up to now, the chromosomal region 10q21.3 has not been identified as a candidate region containing susceptibility genes for autism in any of the linkage studies or in chromosomal aberrations.8
In the future, besides further functional studies, validation of the two candidate genes identified here will rely on association studies in patients and families with autism.
References
Fombonne E : Epidemiology of autistic disorder and other pervasive developmental disorders. J Clin Psychiatry 2005; 66 (Suppl 10): 3–8.
Smalley SL : Genetic influences in childhood-onset psychiatric disorders: autism and attention-deficit/hyperactivity disorder. Am J Hum Genet 1997; 60: 1276–1282.
Barton M, Volkmar F : How commonly are known medical conditions associated with autism? J Autism Dev Disord 1998; 28: 273–278.
Persico AM, Bourgeron T : Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci 2006; 29: 349–358.
Durand CM, Betancur C, Boeckers TM et al: Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 2006; 39: 25–27.
Pickles A, Bolton P, Macdonald H et al: Latent-class analysis of recurrence risks for complex phenotypes with selection and measurement error: a twin and family history study of autism. Am J Hum Genet 1995; 57: 717–726.
Jones MB, Szatmari P : A risk-factor model of epistatic interaction, focusing on autism. Am J Med Genet 2002; 114: 558–565.
Castermans D, Wilquet V, Steyaert J, Van de Ven W, Fryns JP, Devriendt K : Chromosomal anomalies in individuals with autism: a strategy towards the identification of genes involved in autism. Autism 2004; 8: 141–161.
Klauck SM : Genetics of autism spectrum disorder. Eur J Hum Genet 2006; 14: 714–720.
Bacchelli E, Maestrini E : Autism spectrum disorders: molecular genetic advances. Am J Med Genet C Semin Med Genet 2006; 142: 13–23.
Gupta AR, State MW : Recent advances in the genetics of autism. Biol Psychiatry 2006 [Epub ahead of print].
Vorstman JA, Staal WG, van Daalen E, van Engeland H, Hochstenbach PF, Franke L : Identification of novel autism candidate regions through analysis of reported cytogenetic abnormalities associated with autism. Mol Psychiatry 2006; 11: 18–28.
Jacquemont ML, Sanlaville D, Redon R et al: Array- based comparative genomic hybridization identifies high frequency of cryptic chromosomal rearrangements in patients with syndromic autism spectrum disorders. J Med Genet 2006; 43: 843–849.
Castermans D, Wilquet V, Parthoens E et al: The neurobeachin gene is disrupted by a translocation in a patient with idiopathic autism. J Med Genet 2003; 40: 352–356.
Vincent JB, Horike SI, Choufani S et al: An inversion inv(4)(p12-p15.3) in autistic siblings implicates the 4p GABA receptor gene cluster. J Med Genet 2006; 43: 429–434.
Gillberg C : Chromosomal disorders and autism. J Autism Dev Disord 1998; 28: 415–425.
Lauritsen M, Mors O, Mortensen PB, Ewald H : Infantile autism and associated autosomal chromosome abnormalities: a register-based study and a literature survey. J Child Psychol Psychiatry 1999; 40: 335–345.
Folstein SE, Rosen-Sheidley B : Genetics of autism: complex aetiology for a heterogeneous disorder. Nat Rev Genet 2001; 2: 943–955.
Ghaziuddin M, Burmeister M : Deletion of chromosome 2q37 and autism: a distinct subtype? J Autism Dev Disord 1999; 29: 259–263.
Wang NJ, Liu D, Parokonny AS, Schanen NC : High-resolution molecular characterization of 15q11–q13 rearrangements by array comparative genomic hybridization (array CGH) with detection of gene dosage. Am J Hum Genet 2004; 75: 267–281.
Koochek M, Harvard C, Hildebrand MJ et al: 15q duplication associated with autism in a multiplex family with a familial cryptic translocation t(14;15)(q11.2;q13.3) detected using array-CGH. Clin Genet 2006; 69: 124–134.
Vermeesch JR, Melotte C, Froyen G et al: Molecular karyotyping: array CGH quality criteria for constitutional genetic diagnosis. J Histochem Cytochem 2005; 53: 413–422.
Warburton D : De novo balanced chromosome rearrangements and extra marker chromosomes identified at prenatal diagnosis: clinical significance and distribution of breakpoints. Am J Hum Genet 1991; 49: 995–1013.
Jacobs PA, Browne C, Gregson N, Joyce C, White H : Estimates of the frequency of chromosome abnormalities detectable in unselected newborns using moderate levels of banding. J Med Genet 1992; 29: 103–108.
Sambrook J, Fritsch EF, Maniatis T : Molecular cloning: a laboratory manual (second edition). Cold Spring Harbor Laboratory Press: New York, 1989.
Livak KJ, Schmittgen TD : Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402–408.
American Psychiatric Association: DSM-IV – diagnosis and statistical manual of mental disorders (fourth edition) American Psychiatric Publishing: Washington DC, 1994.
Katoh M : Identification and characterization of TRIP8 gene in silico. Int J Mol Med 2003; 12: 817–821.
Calero M, Whittaker GR, Collins RN : Yop1p, the yeast homolog of the polyposis locus protein 1, interacts with Yip1p and negatively regulates cell growth. J Biol Chem 2001; 276: 12100–12112.
Taipale M, Kaminen N, Nopola-Hemmi J et al: A candidate gene for developmental dyslexia encodes a nuclear tetratricopeptide repeat domain protein dynamically regulated in brain. Proc Natl Acad Sci USA 2003; 100: 11553–11558.
Abelson JF, Kwan KY, O'Roak BJ et al: Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science 2005; 310: 317–320.
Clissold PM, Ponting CP : JmjC: cupin metalloenzyme-like domains in jumonji, hairless and phospholipase A2beta. Trends Biochem Sci 2001; 26: 7–9.
Lee JW, Choi HS, Gyuris J, Brent R, Moore DD : Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor. Mol Endocrinol 1995; 9: 243–254.
Anderson GW, Schoonover CM, Jones SA : Control of thyroid hormone action in the developing rat brain. Thyroid 2003; 13: 1039–1056.
London EA : The environment as an etiologic factor in autism: a new direction for research. Environ Health Perspect 2000; 108: 401–404.
Abbassi V, Linscheid T, Coleman M : Triiodothyronine (T3) concentration and therapy in autistic children. J Autism Child Schizophr 1978; 8: 383–387.
Campbell M, Small AM, Hollander CS et al: A controlled crossover study of triiodothyronine in autistic children. J Autism Child Schizophr 1978; 8: 371–381.
Cohen DJ, Young JG, Lowe TL, Harcherik D : Thyroid hormone in autistic children. J Autism Dev Disord 1980; 10: 445–450.
Soldin OP, Lai S, Lamm SH, Mosee S : Lack of a relation between human neonatal thyroxine and pediatric neurobehavioral disorders. Thyroid 2003; 13: 193–198.
Yuan CX, Ito M, Fondell JD, Fu ZY, Roeder RG : The TRAP220 component of a thyroid hormone receptor- associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion. Proc Natl Acad Sci USA 1998; 95: 7939–7944.
Saito H, Kubota M, Roberts RW, Chi Q, Matsunami H : RTP family members induce functional expression of mammalian odorant receptors. Cell 2004; 119: 679–691.
Yang X, Matern HT, Gallwitz D : Specific binding to a novel and essential Golgi membrane protein (Yip1p) functionally links the transport GTPases Ypt1p and Ypt31p. EMBO J 1998; 17: 4954–4963.
Zerial M, McBride H : Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2001; 2: 107–117.
Shen Q, Chen CN, Brands A, Pan SM, Ho TH : The stress- and abscisic acid-induced barley gene HVA22: developmental regulation and homologues in diverse organisms. Plant Mol Biol 2001; 45: 327–340.
Brands A, Ho TH : Function of a plant stress-induced gene, HVA22. Synthetic enhancement screen with its yeast homolog reveals its role in vesicular traffic. Plant Physiol 2002; 130: 1121–1131.
Kleinjan DA, van Heyningen V : Long-range control of gene expression: emerging mechanisms and disruption in disease. Am J Hum Genet 2005; 76: 8–32.
Merla G, Howald C, Henrichsen CN et al: Submicroscopic deletion in patients with Williams–Beuren syndrome influences expression levels of the nonhemizygous flanking genes. Am J Hum Genet 2006; 79: 332–341.
Parnell TJ, Grade SK, Geyer PK, Wallrath LL : Position effect variegation in human genetic disease. Nature Encyclopedia of the Human Genome 2003; 642–646.
Kleinjan DJ, van Heyningen V : Position effect in human genetic disease. Hum Mol Genet 1998; 7: 1611–1618.
Pfeifer D, Kist R, Dewar K et al: Campomelic dysplasia translocation breakpoints are scattered over 1 Mb proximal to SOX9: evidence for an extended control region. Am J Hum Genet 1999; 65: 111–124.
Lettice LA, Heaney SJ, Purdie LA et al: A long-range Shh enhancer regulates expression in the developing limb and fin and is associated with preaxial polydactyly. Hum Mol Genet 2003; 12: 1725–1735.
Berger P, Niemann A, Suter U : Schwann cells and the pathogenesis of inherited motor and sensory neuropathies (Charcot–Marie–Tooth disease). Glia 2006; 54: 243–257.
Acknowledgements
We thank the patient and his family for their cooperation. The excellent technical assistance of Reinhilde Thoelen performing the FISH analyses is gratefully acknowledged. We would like to thank Marijke Bauters for her very kind assistance on real-time PCR and Bernard Thienpont for performing the aCGH analysis on the proband. This work is supported by a grant from Interuniversitary Attraction Poles (IAP-P5/25, Belgian State), from Geconcerteerde Onderzoeksacties (GOA2002/010, Belgium) and from the Fund for Scientific Research-Flanders (FWO G0264.04, Belgium). KD is a Senior Clinical Investigator of FWO.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Castermans, D., Vermeesch, J., Fryns, JP. et al. Identification and characterization of the TRIP8 and REEP3 genes on chromosome 10q21.3 as novel candidate genes for autism. Eur J Hum Genet 15, 422–431 (2007). https://doi.org/10.1038/sj.ejhg.5201785
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ejhg.5201785
Keywords
This article is cited by
-
Genome-wide interaction study with major depression identifies novel variants associated with cognitive function
Molecular Psychiatry (2022)
-
Mutation load at a mimicry supergene sheds new light on the evolution of inversion polymorphisms
Nature Genetics (2021)
-
Whole genome sequencing of nearly isogenic WMI and WLI inbred rats identifies genes potentially involved in depression and stress reactivity
Scientific Reports (2021)
-
Copy Number Variants in Patients with Autism and Additional Clinical Features: Report of VIPR2 Duplication and a Novel Microduplication Syndrome
Molecular Neurobiology (2017)
-
Progress in the detection of human genome structural variations
Science in China Series C: Life Sciences (2009)